Outlook Therapeutics, Inc. announced the appointments of Surendra Sharma, MD, as Senior Vice President, Medical Affairs, and Glen Olsheim as Executive Director, Commercial Excellence. Outlook Therapeutics is very happy to welcome Surendra and Glen to growing executive leadership team. Their respective backgrounds in directing the medical affairs of an ophthalmic portfolio and of driving the successful launch and commercialization of ophthalmic products will be tremendously valuable as move towards the commercial launch of ONS-5010 ophthalmic bevacizumab, pending its approval by the U.S. FDA, said Russell Trenary, President and Chief Executive Officer of Outlook Therapeutics.

Dr. Sharma has more than 15 years of experience in the pharmaceutical and biotechnology industries leading corporate alliances among R&D, commercial, marketing and business stakeholders. Most recently, he was Senior Medical Director, Cornea, Dry Eye and Retina, Global Medical Affairs at Santen Pharmaceuticals Ltd. Over the course of his career at companies including Spark Therapeutics, Inc., Biogen Inc., Alcon Laboratories, Inc. and Regeneron Pharmaceuticals, Inc., he led global scientific communications strategies designed to align and meet the needs of key stakeholders in the North American and global markets. Dr. Sharmas ability to create and maintain key relationships between the Company and key opinion leaders, the medical and scientific community, patients and advocacy groups, health authorities, and regulatory agencies will be instrumental for Outlook Therapeutics potential launch and commercialization of ONS-5010 ophthalmic bevacizumab.

In his new role as SVP of Medical Affairs, Dr. Sharma will report to Russ Trenary, President and Chief Executive Officer of Outlook Therapeutics. Mr. Olsheim brings to Outlook Therapeutics more than 15 years of product commercialization experience in ophthalmology. Prior to joining Outlook Therapeutics, in his role as the VP of Business and New Product Development at Fagron Sterile Services, he focused on driving revenue, profit and value in repackaging IV bevacizumab for ophthalmic use in retina indications.

His familiarity with marketing these off-label products for sale to ophthalmologists brings specific focus to his strong network of industry contacts from major eye institutes and hospitals. His experience and networks will be important for the potential launch and commercialization of ONS-5010 ophthalmic bevacizumab. In his new role as Executive Director of Commercial Excellence, Mr. Olsheim will report to Jeff Evanson, Chief Commercial Officer of Outlook Therapeutics, to help deliver an industry-leading customer experience.